Modality
Bispecific Ab
MOA
FcRni
Target
MALT1
Pathway
Lipid Met
Crohn's
Development Pipeline
Preclinical
~Jul 2018
→ ~Oct 2019
Phase 1
Jan 2020
→ Apr 2026
Phase 1Current
NCT03182882
1,279 pts·Crohn's
2022-06→TBD·Active
NCT07647911
528 pts·Crohn's
2020-01→2026-04·Not yet recruiting
1,807 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-04-142w awayInterim· Crohn's
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
P1
Not yet…
P1
Active
Catalysts
Interim
2026-04-14 · 2w away
Crohn's
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03182882 | Phase 1 | Crohn's | Active | 1279 | UPDRS |
| NCT07647911 | Phase 1 | Crohn's | Not yet recr... | 528 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 | |
| Cevisacituzumab | Alnylam | Preclinical | MALT1 | |
| ION-8812 | Ionis | Phase 1 | MALT1 |